Lipegfilgrastim (Lonquex®)

Assessment Status Rapid Review Complete
Drug Lipegfilgrastim
Brand Lonquex®
Indication For reduction in the duration of neutropenia and the incidence of febrile neutropenia in adult patients treated with cytotoxic chemotherapy for malignancy (with the exception of chronic myeloid leukaemia and myelodysplastic syndromes).
Assessment Process
Rapid review commissioned 20/08/2013
Rapid review completed 20/09/2013
Rapid review outcome Full Pharmacoeconomic Assessment Not Recommended